Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-thymosin alpha1 plus adefovir vs adefovir in HBeAg-positive chronic hepatitis B
CTR20132851Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of polyethylene glycol thymosin alpha1 in Chronic hepatitis B (CHB), sponsored by Hengrui Therapeutics. Started Jan 2015; status: active.
02
Drugs
polyethylene glycol thymosin alpha1
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20132851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132851.